Table 2. BMI before and at diagnosis and overall and ovarian cancer-specific mortality (KP-ROCS study, 2000–2014)a.
| No. | Events | HRb (95% CI) | HRc (95% CI) | HRd (95% CI) | |
|---|---|---|---|---|---|
|
Overall mortality | |||||
| Prediagnosis BMI (kg m−2) | |||||
| Normal (18.5–24.99) | 372 | 185 | 1 (reference) | 1 (reference) | 1 (reference) |
| Overweight (25–29.99) | 383 | 201 | 0.95 (0.77–1.16) | 0.80 (0.65–0.99) | 0.82 (0.65–1.03) |
| Obese I (30–34.99) | 218 | 112 | 0.98 (0.77–1.25) | 0.96 (0.74–1.23) | 0.99 (0.76–1.29) |
| Obese II (35–39.99) | 106 | 58 | 0.96 (0.71–1.31) | 0.89 (0.64–1.22) | 0.92 (0.65–1.30) |
| Obese III (⩾40) | 95 | 50 | 1.08 (0.78–1.50) | 0.95 (0.67–1.36) | 1.02 (0.70–1.47) |
| At-diagnosis BMI (kg m−2) | |||||
| Normal (18.5–24.99) | 407 | 205 | 1 (reference) | 1 (reference) | 1 (reference) |
| Overweight (25–29.99) | 374 | 189 | 0.86 (0.70–1.06) | 0.81 (0.65–0.99) | 0.81 (0.65–1.02) |
| Obese I (30–34.99) | 201 | 108 | 0.89 (0.70–1.14) | 0.93 (0.72–1.19) | 0.87 (0.67–1.14) |
| Obese II (35–39.99) | 105 | 55 | 0.85 (0.62–1.16) | 0.87 (0.63–1.20) | 0.82 (0.57–1.16) |
| Obese III (⩾40) | 76 | 40 | 1.50 (1.06–2.13) | 1.20 (0.82–1.76) | 1.24 (0.83–1.85) |
|
Ovarian cancer-specific mortality | |||||
| Prediagnosis BMI (kg m−2) | |||||
| Normal (18.5–24.99) | 372 | 158 | 1 (reference) | 1 (reference) | 1 (reference) |
| Overweight (25–29.99) | 383 | 174 | 0.96 (0.77–1.19) | 0.83 (0.66–1.04) | 0.84 (0.66–1.08) |
| Obese I (30–34.99) | 218 | 89 | 0.90 (0.69–1.18) | 0.89 (0.68–1.18) | 0.92 (0.69–1.24) |
| Obese II (35–39.99) | 106 | 51 | 0.98 (0.70–1.36) | 0.92 (0.65–1.30) | 0.96 (0.67–1.39) |
| Obese III (⩾40) | 95 | 43 | 1.10 (0.77–1.56) | 0.96 (0.66–1.40) | 1.01 (0.68–1.50) |
| At-diagnosis BMI (kg m−2) | |||||
| Normal (18.5–24.99) | 407 | 177 | 1 (reference) | 1 (reference) | 1 (reference) |
| Overweight (25–29.99) | 374 | 166 | 0.87 (0.70–1.08) | 0.82 (0.66–1.03) | 0.82 (0.64–1.04) |
| Obese I (30–34.99) | 201 | 85 | 0.80 (0.61–1.04) | 0.84 (0.63–1.10) | 0.78 (0.58–1.05) |
| Obese II (35–39.99) | 105 | 47 | 0.84 (0.60–1.18) | 0.85 (0.60–1.22) | 0.78 (0.53–1.14) |
| Obese III (⩾40) | 76 | 33 | 1.43 (0.97–2.10) | 1.15 (0.75–1.74) | 1.17 (0.75–1.81) |
Abbreviations: BMI=body mass index; CA125=cancer antigen 125; CI=confidence interval; CVD=cardiovascular disease; KP-ROCS=Kaiser Permanente Research on Ovarian Cancer Survival; HR=hazard ratio.
a
Underweight women (n=10 for ‘prediagnosis’/n=21 for ‘at diagnosis’ analyses) were excluded.
b
Adjusted for age at diagnosis, race/ethnicity, stage, histology, grade, and time of the BMI measure relative to time of diagnosis (months).
c
Further adjusted for diabetes, hypertension, CVD, renal disease, post-treatment CA125, chemotherapy (no, carboplatin+paclitaxel, other regimen). and type of surgery.
d
Further adjusted for ascites and bowel obstruction and excluding women with cachexia.